Sodium tungstate regulates food intake and body weight through activation of the hypothalamic leptin pathway

Diabetes, Obesity and Metabolism

Volumn 13, Issue 3, 2011, Pages 235-242

  Amigo Correig M ^a,b,c   Barcelo Batllori S ^a,b   Piquer, S ^a,b   Soty, M ^a,b   Pujadas, G ^a,b   Gasa, R ^a,b   Bortolozzi, A ^d   Carmona, M C ^a,b   Gomis, R ^a,b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INST D INVESTIGACIONS B   (Spain)

Author keywords

AgRP; Anti obesity drug; Appetite control; Drug mechanism; Energy regulation; ERK1 2; Hypothalamus; JAK2; Leptin; Neuropharmacology; NPY; Obesity; Obesity therapy; Sodium tungstate

Indexed keywords

ACTIN; AGOUTI RELATED PROTEIN; ANTIOBESITY AGENT; JANUS KINASE 2; LEPTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT PROTEIN; STAT3 PROTEIN; TUNGSTATE SODIUM; UNCLASSIFIED DRUG;

AGRP GENE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; ENERGY EXPENDITURE; ENZYME ACTIVITY; FOOD INTAKE; GENE; GENE EXPRESSION REGULATION; HYPOTHALAMUS; IN VITRO STUDY; LIPID OXIDATION; MALE; MASS SPECTROMETRY; NONHUMAN; OBESITY; ONCOGENE C FOS; ONCOGENE C MYC; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WISTAR RAT;

EID: 78851470972     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01339.x     Document Type: Article

References (43)

1. Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 2009; 16: 693-704.
2. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-671.
3. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
4. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
5. Montague CT, Farooqi IS, Whitehead JP et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-908.
6. Meister B. Control of food intake via leptin receptors in the hypothalamus. Vitam Horm 2000; 59: 265-304.
7. Woods SC, D'Alessio DA. Central control of body weight and appetite. J Clin Endocrinol Metab 2008; 93: S37-50.
8. Gong L, Yao F, Hockman K et al. Signal transducer and activator of transcription-3 is required in hypothalamic agouti-related protein/neuropeptide Y neurons for normal energy homeostasis. Endocrinology 2008; 149: 3346-3354.
9. Thornton JE, Cheung CC, Clifton DK, Steiner RA. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 1997; 138: 5063-5066.
10. Kristensen P, Judge ME, Thim L et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998; 393: 72-76.
11. Villanueva EC, Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Int J Obes (Lond) 2008; 32(Suppl. 7): S8-12.
12. Hubschle T, Thom E, Watson A, Roth J, Klaus S, Meyerhof W. Leptin-induced nuclear translocation of STAT3 immunoreactivity in hypothalamic nuclei involved in body weight regulation. J Neurosci 2001; 21: 2413-2424.
13. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995; 82: 241-250.
14. O'Rourke L, Shepherd PR. Biphasic regulation of extracellular-signal-regulated protein kinase by leptin in macrophages: role in regulating STAT3 Ser727 phosphorylation and DNA binding. Biochem J 2002; 364: 875-879.
15. Rahmouni K, Sigmund CD, Haynes WG, Mark AL. Hypothalamic ERK mediates the anorectic and thermogenic sympathetic effects of leptin. Diabetes 2009; 58: 536-542.
16. Elias CF, Aschkenasi C, Lee C et al. Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron 1999; 23: 775-786.
17. Bjorbak C, Buchholz RM, Davis SM et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 2001; 276: 4747-4755.
18. Kopelman PG, Grace C. New thoughts on managing obesity. Gut 2004; 53: 1044-1053.
19. Claret M, Corominola H, Canals I et al. Tungstate decreases weight gain and adiposity in obese rats through increased thermogenesis and lipid oxidation. Endocrinology 2005; 146: 4362-4369.
20. Munoz MC, Barbera A, Dominguez J, Fernandez-Alvarez J, Gomis R, Guinovart JJ. Effects of tungstate, a new potential oral antidiabetic agent, in Zucker diabetic fatty rats. Diabetes 2001; 50: 131-138.
21. Carmona MC, Amigo M, Barcelo-Batllori S et al. Dual effects of sodium tungstate on adipocyte biology: inhibition of adipogenesis and stimulation of cellular oxygen consumption. Int J Obes (Lond) 2009; 33: 534-540.
22. Barcelo-Batllori S, Corominola H, Claret M, Canals I, Guinovart J, Gomis R. Target identification of the novel antiobesity agent tungstate in adipose tissue from obese rats. Proteomics 2005; 5: 4927-4935.
23. Barcelo-Batllori S, Kalko SG, Esteban Y, Moreno S, Carmona MC, Gomis R. Integration of DIGE and bioinformatics analyses reveals a role of the antiobesity agent tungstate in redox and energy homeostasis pathways in brown adipose tissue. Mol Cell Proteomics 2008; 7: 378-393.
24. Canals I, Carmona MC, Amigo M et al. A functional leptin system is essential for sodium tungstate antiobesity action. Endocrinology 2009; 150: 642-650.
25. Le Lamer S, Poucheret P, Cros G, de Richter RK, Bonnet PA, Bressolle F. Pharmacokinetics of sodium tungstate in rat and dog: a population approach. J Pharmacol Exp Ther. 2000; 294: 714-721.
26. Sophie Le L, Gérard C, Carmen P, Josepha F-A, Françoise B. An application of population kinetics analysis to estimate pharmacokinetic parameters of sodium tungstate after multiple-dose during preclinical studies in rats. Pharmacol Toxicol 2002; 90: 100-105.
27. Le Lamer S, Cros G, Serrano J-J, Piñol C, Fernändez-Alvarez J, Bressolle F. Estimation of pharmacokinetic parameters of sodium tungstate after multiple-dose during preclinical studies in beagle dogs. Eur J Pharm Sci 2001; 14: 323-329.
28. Le Lamer-Déchamps S, Poucheret P, Cros G, Bressolle F. Influence of food and diabetes on pharmacokinetics of sodium tungstate in rat. Int J Pharm 2002; 248: 131-139.
29. Belsham DD, Cai F, Cui H, Smukler SR, Salapatek AM, Shkreta L. Generation of a phenotypic array of hypothalamic neuronal cell models to study complex neuroendocrine disorders. Endocrinology 2004; 145: 393-400.
30. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998; 22(Suppl. 1): S18-28; discussion S29.
31. Zanella MT, Ribeiro Filho FF. Emerging drugs for obesity therapy. Arq Bras Endocrinol Metabol 2009; 53: 271-280.
32. Akbas F, Gasteyger C, Sjodin A, Astrup A, Larsen TM. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 2009; 10: 58-67.
33. Roth JD, Roland BL, Cole RL et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 2008; 105: 7257-7262.
34. Foster JD, Young SE, Brandt TD, Nordlie RC. Tungstate: a potent inhibitor of multifunctional glucose-6-phosphatase. Arch Biochem Biophys 1998; 354: 125-132.
35. Katoh M, Katoh M. STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (review). Int J Mol Med 2007; 19: 273-278.
36. Basu A, Meyer K, Lai KK et al. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 2006; 349: 347-358.
37. Bates SH, Stearns WH, Dundon TA et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 2003; 421: 856-859.
38. Morrison CD, Morton GJ, Niswender KD, Gelling RW, Schwartz MW. Leptin inhibits hypothalamic Npy and AgRP gene expression via a mechanism that requires phosphatidylinositol 3-OH-kinase signaling. Am J Physiol Endocrinol Metab 2005; 289: E1051-E1057.
39. Mayer CM, Belsham DD. Insulin directly regulates NPY and AgRP gene expression via the MAPK MEK/ERK signal transduction pathway in mHypoE-46 hypothalamic neurons. Mol Cell Endocrinol 2009; 307: 99-108.
40. Xu AW, Kaelin CB, Takeda K, Akira S, Schwartz MW, Barsh GS. PI3K integrates the action of insulin and leptin on hypothalamic neurons. J Clin Invest 2005; 115: 951-958.
41. Kuo DY, Yang SF, Chu SC, Chu SC, Chen CH, Hsieh YS. Amphetamine-evoked changes of oxidative stress and neuropeptide Y gene expression in hypothalamus: regulation by the protein kinase C-delta signaling. Chem Biol Interact 2009; 180: 193-201.
42. Brown RE, Wilkinson PM, Imran SA, Wilkinson M. Resistin differentially modulates neuropeptide gene expression and AMP-activated protein kinase activity in N-1 hypothalamic neurons. Brain Res 2009; 1294: 52-60.
43. Scarpace PJ, Zhang Y. Leptin resistance: a prediposing factor for diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2009; 296: R493-R500.